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e-mail addresses: abdozkaya@gmail.com, abdozkaya@mynet.com (A. Ozkaya).Abdullah Ozkaya, MD a,⇑; Zeynep Alkin, MD a; Miray Faiz, MD a; Ahmet Taylan Yazici, MD a; Ahmet Demirok, Dr. a,bAbstractThe aim of this study is to report clinical course of choroidal neovascularization secondary to angioid streaks (AS) in two patients
who underwent intravitreal bevacizumab therapy. Fundus examination, fluorescein angiography (FA) and optical coherence
tomography (OCT) revealed the diagnosis of subfoveal classic choroidal neovascularization (CNV) in the right eye in patient 1
and in the left eye in patient 2. After three consecutive bevacizumab injections, visual acuity improved from 20/40 to 20/25 in
patient 1 and from 20/80 to 20/50 in patient 2. After 3 months of therapy, additional bevacizumab injection was administered
when the lesion showed recurrence. After a follow-up time of 24-months, patient 1 received 14 intravitreal bevacizumab injections;
patient 2 received only 4 injections. Visual acuities remained stable at 20/32 and 20/50 in patient 1 and patient 2, respectively.
Though, the patients of CNV secondary to AS showed similar clinical appearance at the beginning, this report provides the data
for different responses to intravitreal bevacizumab therapy. While fewer injections were required to control the disease in one
patient, the other patient needed much more injections for stabilization of the CNV. Further studies are required to understand
the cause of varied treatment responses in those patients.
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Angioid streaks (AS) were first reported by Doyne1 in 1889
in a patient who had suffered from retinal hemorrhage sec-
ondary to trauma. Knapp first used the term of ‘angioid
streaks’ because their appearance suggested a vascular ori-
gin.2 Later, the histopathological findings revealed that the
underlying abnormality was structural alterations in Bruch’s
membrane rather than a vascular pathology. They are de-
scribed as lesions with irregular lines radiating from the optic
nerve head to the peripheral retina and result from rupture or
dehiscence of a calcified and brittle Bruch’s membrane be-
tween the retinal pigment epithelium and the choroid.3
Angioid streaks may accompany many systemic dis-
eases, such as pseudoxanthoma elasticum, Paget’s disease,Ehler–Danlos syndrome, and hemoglobinopathies. Ocular
findings of angioid streaks include bilateral, narrow, jagged
lines radiating from the optic nerve to the peripheral retina,
peau d’orange pigmentary pattern in the retina and second-
ary choroidal neovascularization.3 The aim of this study is to
present two patients of choroidal neovascularization second-
ary to angioid streaks, both associated with pseudoxanthoma
elasticum.
Case reports
Case 1
A thirty-seven-year-old male patient presented with
blurred vision in the right eye and a decrease in vision ine:
al.com
Figure 2. Optical coherence tomography scan demonstrates a hyperre-
flective subfoveal choroidal neovascular membrane with subretinal fluid
before therapy.
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low skin papules and plaques located laterally on his neck
and arm pits. His family history was not significant. On ocular
examination, best corrected visual acuity (BCVA) was 20/40 in
his right eye and 20/800 in his left eye. Slit lamp examination
of the anterior segment did not show any abnormality. Intra-
ocular pressure was within normal limits in both eyes. Fundus
examination revealed peripapillary angioid streaks branching
radially from the optic disk and peau d’orange pigmentary
pattern in both eyes. A grayish subfoveal lesion surrounded
by subretinal hemorrhages in his right eye, and disciform
scarring were noticed in the left eye (Fig. 1). Fundus fluores-
cein angiography (FA) showed window defect hyperfluores-
cence in both his eyes at the areas in correspondence with
angioid streaks, a subfoveal classic choroidal neovasculariza-
tion associated with leakage and hemorrhages in his right eye
and a subfoveal classic CNV scar in his left eye. Optical coher-
ence tomography (OCT) revealed subfoveal classic CNV
associated with subretinal fluid collection in the right eye
(Fig. 2), and a classic CNV scar in the left eye. The central ret-
inal thickness was 261 and 140 microns, respectively in the
right and left eye. Based on ocular and dermatologic find-
ings, the patient’s diagnosis was thought to be pseudoxan-
thoma elasticum and he was referred to the dermatology
clinic. Pathologic examination of the skin biopsy specimen
from his neck showed deposition of calcium and degener-
ated, clumped, fragmented elastic fibers staining with Ver-
hoeff-van Gieson stain in the deep reticular dermis,
confirming the diagnosis of pseudoxanthoma elasticum.
The patient was also referred to gastroenterology, and to
cardiology clinics for preventive care. Gastroscopic, colono-
scopic, and cardiac evaluation were normal. At each follow-
up visit, measurement of BCVA and intraocular pressure
and, OCT evaluation were performed. FA was performed
when needed. As initial therapy, the patient received three
consecutive 1.25 mg/0.5 mL intravitreal bevacizumab injec-
tions every 4 weeks in the right eye. After three consecutive
bevacizumab injections, BCVA in the right eye improved from
20/40 to 20/25, OCT showed absence of subretinal fluid, and
CMT was decreased from 261 to 188 microns. At 6 month’s
visit, BCVA decreased from 20/25 to 20/32 and OCT re-
vealed subretinal fluid (Fig. 3); an additional bevacizumab
injection was given. After the 4th intravitreal injection, BCVA
remained stable at 20/32 and OCT showed absence of sub-
retinal fluid. Additional treatment was administered when
the lesion showed subretinal or intraretinal fluid on OCT,
leakage on FFA, intraretinal or subretinal hemorrhage in
the examination, or when a decreasing visual acuity wasFigure 1. Color fundus photograph of patient 1. Peripapillary angioid
streaks branching radially from the optic disk are seen in both of the eyes
(OD and OS). The white arrow points the grayish subfoveal choroidal
neovascularization in the right eye, white stars point the subretinal
hemorrhages around the macula (OD). There is a disciform scarring at the
macula on the left eye (OS).detected. After a follow up period of 24 months the patients
received a total of 14 intravitreal bevacizumab injections and
BCVA was measured 20/32. OCT did not show subretinal
fluid either (Fig. 4). No serious adverse events related to
intravitreal injection of bevacizumab occurred.Case 2
A forty-four-year-old female patient presented to our
clinic with a decrease in vision in her left eye in August
2010. Systemic evaluation showed several yellow skin pap-
ules and plaques located laterally on her neck and arm pits.
She did not have any other systemic diseases. On ocular
examination, BCVA was 20/25 in the right eye and 20/80 in
the left eye. Slit lamp examination of the anterior segment
did not show any abnormality. Intraocular pressure was within
normal limits in both eyes. Fundus examination revealed per-
ipapillary angioid streaks branching radially from the optic
disk in both eyes; mild pigmentary changes at the macula
in the right eye, a grayish subfoveal lesion and scarring in
the left eye (Fig. 5). FA showed a window defect hyperfluo-
rescence in both her eyes at the areas in correspondence with
angioid streaks, a subfoveal classic choroidal neovasculariza-
tion associated with leakage and in the left eye. OCT did not
reveal any abnormality in the right eye; however, a subfoveal
classic CNV associated with minimal subretinal fluid collec-
tion was detected in the left eye. The central retinal thickness
was 147 and 195 microns, respectively in the right and left
eye. Follow-up examinations were carried out one week after
the intravitreal injections and then monthly for follow-up per-
iod. For each visit, BCVA and intraocular pressure were mea-
sured and, side effects and complications resulting from
intravitreal injection were assessed. While OCT was per-
formed in each visit, FA was used as needed. As initial ther-
apy, the patient received three consecutive intravitrealFigure 3. Optical coherence tomography reveals the recurrence of
choroidal neovascular membrane activity with minimal subretinal fluid
collection at 6 months’ visit.
Figure 4. Optical coherence tomography shows choroidal neovascular
membrane and absence of subretinal fluid collection at 24 months of
therapy.
318 A. Ozkaya et al.bevacizumab injections of 1.25 mg/0.5 mL. After three con-
secutive bevacizumab injections, BCVA in the right eye im-
proved from 20/80 to 20/50, OCT showed absence of
subretinal fluid, and CMT was decreased from 195 to 154 mi-
crons. Additional treatment was administered when the le-
sion showed subretinal or intraretinal fluid on OCT, leakage
on FA, intraretinal or subretinal hemorrhage in the examina-
tion, or when a decreasing visual acuity was detected. After a
follow up period of 24 months, the patient received a total of
four intravitreal bevacizumab injections and BCVA was stable
at 20/50 and OCT did not show subretinal fluid. No injection
related serious ocular and systemic complications were
observed.Discussion
The hallmark of AS, results from degeneration and calcifi-
cation of the elastic fibers in Bruch’s membrane which leads
to multiple breaks. These breaks may cause CNV, subretinal
hemorrhages, retinal hemorrhages, and visual loss.4 Usually,
the first sign of the angioid streaks is peau d’orange and it
may be seen even 10 years before the formation of angioid
streaks.3,4 The visual acuity remains unchanged unless a
break or a CNV affects macula. There is no proven effective
therapy for breaks yet; however, CNV may be treated with la-
ser photocoagulation, intravitreal anti-VEGF injections and
photodynamic therapy.3–5 Cekic et al.,6 reported that intravi-
treal pegaptanib sodium was effective in preventing visual
acuity loss in five eyes of four patients after a median fol-
low-up time of 18 months. They also noted that two of the
eyes had a visual improvement. In a retrospective study by
Wiegand et al.,7 it is reported that intravitreal bevacizumab
injection was effective in preventing visual loss in 88.8% pa-
tients with CNV secondary to angioid streaks. In a study
which had a mean follow-up time of 23.8 months by NeriFigure 5. Color fundus photograph of patient 2. Peripapillary angioid
streaks branching radially from the optic disk are seen in both of the eyes
(OD and OS). The white arrow points the grayish subfoveal choroidal
neovascularization in the left eye (OS).et al.,8 it is cited that all 11 patients remained stable or had
improved vision. In two case reports; Nika et al.4 and Japi-
assu et al.9 reported successful results with intravitreal bev-
acizumab in CNV secondary to angioid streaks. Intravitreal
ranibizumab injection and combination treatments (PDT
and intravitreal anti-VEGF injection) are the other treatment
modalities which are used for the treatment of CNV second-
ary to angioid streaks.5,9 Finger10 reported successful results
with intravitreal ranibizumab in a case series of 7 patients.
Prabhu et al.5 reported that combination treatment of low
fluence PDT and intravitreal ranibizumab injection was effec-
tive for choroidal neovascularization secondary to AS in a
case report.
Choroidal neovascularizations are usually associated with
sudden visual loss. Intravitreal anti-VEGF treatment is an
effective treatment option for the CNVs associated with AS
and proven effective up to 2 years.5–10 The natural course
of AS is similar to age-related macular degeneration, because
the disease has a progressive nature.3 In this study we pre-
sented two different angioid streaks patients.
Both patients suffered from CNV secondary to pseudo-
xanthoma elasticum. Interestingly, the first patient had a
chronic and unfavorable clinical course requiring many intra-
vitreal injections; however, the second patient had a better
clinical course requiring very few intravitreal injections. In
the light of these findings, bevacizumab appears to be a safe
and effective treatment for CNV secondary to AS. Future
studies are required to validate these findings and to under-
stand patient characteristics which could affect the treatment
response.
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